Comparison of administration of platelet concentrates suspended in M-sol or BRS-A for pediatric patients.
Two different platelet additive solutions (PASs), M-sol and BRS-A, used in succession, have been reported as novel PASs in Japan. However, there are not enough clinical data comparing platelet concentrates (PCs) suspended in these PASs. A retrospective cohort study of consecutive cases was performed between 2013 and 2018. For the first 30 months, children with primary hematologic and/or malignant diseases were transfused resuspended PCs in M-sol (RPC-M) as plasma-replaced PCs. For the subsequent 30 months, children were transfused plasma-replaced PCs in BRS-A (RPC-B) under the same conditions. Children transfused with conventional PCs (containing residual plasma) were defined as controls. We evaluated the frequency of adverse events, corrected count increment (CCI), and bleeding occurrence in the children. Overall, 84 patients received 679 conventional PC transfusions. Allergic transfusion reactions (ATRs) occurred in 12 (14.3%) patients transfused with 12 (1.8%) bags. Fifty-nine patients received a total of 1182 bags of RPC-M, and one patient (1.7%) had five (0.4%) ATR episodes. During the last 30 months, 58 patients were transfused 1044 bags of RPC-B, with ATRs occurring in four (6.9%) patients transfused with four (0.4%) bags. No other adverse events were observed with either RPC-M or RPC-B. CCIs (24 hr) were not significantly different for the three different PCs, and posttransfusion bleeding was not observed. Plasma-replaced PC using two different PAS in children appeared to prevent ATRs accompanied without other adverse events in children. Transfusion efficacy was not significant; therefore, either of the PASs could be used with equivalent results based on the clinical situation.